Please assess the completion status of the following clinical trial:

Trial Title: Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with diagnosis of CP-CML with cytogenetic confirmation of Philadelphia (Ph) chromosome~* Ph negative cases or patients with variant translocations who are BCR-ABL positive in multiplex PCR are also eligible~* WHO performance status 0-2~* Laboratory assessments within normal limits~* Written informed consent prior to any study procedures being performed~Exclusion Criteria:~* Known impaired cardiac function~* History of acute or chronic pancreatitis~* Impaired gastrointestinal function or disease that may alter the absorption of study drug~* Concomitant medications with potential QT prolongation, or known to interact with CYP450 isoenzymes (CYP3A4, CYP2C9, and CYP2C8)~* Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy~* Patients who are pregnant or breast feeding, or females of reproductive potential not employing an effective method of birth control. Female patients must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nilotinib (Type: EXPERIMENTAL): This was a single-arm study; therefore all participants received nilotinib (AMN107) 300 mg bid given as two 150 mg capsules twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).